Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 16,133 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Early-Stage Breast Cancer
Interventions: Patient Assistance, Information only; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 8
States / cities: New York, New York • Queens, New York

Conditions: Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer
Interventions: OncoPrism™ assay; Diagnostic Test
Lead sponsor: Cofactor Genomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acne Vulgaris
Interventions: Benzoyl Peroxide, Moisturizing Lotion; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Warts, HPV
Interventions: Candida Antigen; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Alopecia Areata
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Rosacea
Interventions: Minocycline hydrochloride capsules, Placebo; Drug · Other
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Las Cruces, New Mexico • El Paso, Texas

Conditions: Facial Dermatoses, Seborrheic Keratoses
Interventions: Pulsed dye laser, Curettage, Electrodesiccation, No treatment; Device · Procedure · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod; Procedure · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Melanoma, Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck
Interventions: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594); Drug
Lead sponsor: Jennerex Biotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Billings, Montana • Philadelphia, Pennsylvania • Greenville, South Carolina

Conditions: Diabetic Foot, Diabetic Peripheral Neuropathy
Interventions: Orpyx SI® Sensory Insole System; Device
Lead sponsor: Orpyx Medical Technologies Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Circleville, Ohio

Conditions: Diabetic Foot Ulcer
Interventions: Not listed
Lead sponsor: Boise VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Malignant Skin Neoplasm, Skin Disorder, Skin Neoplasm
Interventions: Quantitative Oblique Back-Illumination Microscopy, Radiation Therapy; Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetic Foot Ulcers
Interventions: Prevention of Pressure Ulcers; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne Vulgaris
Interventions: Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: West Covina, California • Brandon, Florida • Fort Lauderdale, Florida + 9 more

Conditions: Breast Cancer
Interventions: Photon, 3D-Proton/Conventional plan or 3D-proton only; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Metastatic Breast Cancer
Interventions: Lasofoxifene and abemaciclib (VERZENIO (R)).; Drug
Lead sponsor: Sermonix Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Yuma, Arizona • Fountain Valley, California + 12 more

Conditions: Behcet's Disease, Churg-Strauss Syndrome, Vasculitis, Central Nervous System, Giant Cell Arteritis, Wegener Granulomatosis, Henoch-Schoenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Obesity
Interventions: Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cutaneous Lupus Erythematosus (CLE)
Interventions: Lenalidomide; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Intrahepatic Cholestasis of Pregnancy
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Diabetic Foot Ulcer
Interventions: Chlorhexidine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Radiomics on MRI, microbubble CEUS Contrast Enhanced Ultrasound (CEUS); Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Solid Tumors With and Without Brain Metastases
Interventions: ANG1005; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Canton, Ohio • Houston, Texas • San Antonio, Texas

Conditions: Breast Cancer
Interventions: Dexmedetomidine, Liposomal bupivacaine; Drug
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portsmouth, Virginia

Search by objective public record fields.

Patient Centered Randomized Controlled Trial

A Multicenter Cancer Biospecimen Collection Study

Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris

Study With Candida Antigen for Treatment of Warts

A Study of Secukinumab for the Treatment of Alopecia Areata

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

Dermatosis Papulosa Nigra

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors

Monitoring Physiologic Parameters in Individuals With Diabetic Peripheral Neuropathy

Prevention of Amputation in Diabetic Foot Ulcers Using Amniotic Tissue

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

Investigation of Subatmospheric Pressure Dressing on Pressure Ulcer Healing

Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris

Proton Therapy for Lymph Nodes in Breast Cancer

Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Educational Needs of Patients With Systemic Vasculitis

Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Preventing Diabetic Foot Ulcers Through Cleaner Feet

Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer

Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies